| Metric | Value ($ M) | Q1 FY26 | Q2 FY25 |
|---|---|---|---|
| Revenue | 297.98 | 4.4% | 35.8% |
| Total Income | 297.98 | 4.4% | 35.8% |
| Expenditure | 280.80 | 4.8% | 35.0% |
| PBT | 14.83 | 5.3% | 40.2% |
| Net Profit | 9.08 | 6.6% | 28.1% |
| OPM | 5.77% | 0.30pp | 0.52pp |
| NPM | 3.05% | 0.06pp | 0.18pp |
| EPS | 0.26 | 4.0% | 23.8% |
Pennant Reports Second Quarter 2026 Results
06 Aug 2026 · 6 Aug, 1:53 am
Summary
The Pennant Group, Inc. reported strong second quarter 2026 results, with total revenue increasing by 35.8% year-over-year to $298.0 million. Net income rose by 28.2% to $9.1 million, while adjusted net income grew by 36.5% to $12.8 million. Management expressed confidence in exceeding full-year guidance, driven by operational excellence across both segments and successful integration of recent acquisitions.
Key Highlights
- 1
Total revenue for the second quarter was $298.0 million, an increase of $78.5 million or 35.8% over the prior year quarter.
- 2
Net income for the second quarter was $9.1 million, an increase of $2.0 million or 28.2% over the prior year quarter.
- 3
Adjusted net income for the second quarter was $12.8 million, an increase of $3.4 million or 36.5% over the prior year quarter.
- 4
Consolidated Adjusted EBITDAR for the second quarter was $37.6 million, an increase of $9.4 million or 33.3% over the prior year quarter.
- 5
Home Health and Hospice Services segment revenue for the second quarter was $237.8 million, an increase of $71.8 million or 43.2% over the prior year quarter.
- 6
Senior Living Services segment revenue for the second quarter was $60.2 million, an increase of $6.7 million or 12.6% over the prior year quarter.
- 7
Total home health admissions for the second quarter were 28,947, an increase of 11,115 or 62.3% over the prior year quarter.
Management Comments
Brent Guerisoli
Pennant delivered another strong quarter, putting us on pace to exceed the top end of our original full year guidance. We are driving operational excellence across both segments, including at our recently-acquired operations in the southeast, even as we complete their integration. That process is unfolding ahead of our expectations, and we are now transitioning the two largest waves of operations, which we expect to fully complete by the middle of the fourth quarter.
John Gochnour
Our segments continue to deliver healthy growth. We have been focused on operational excellence at every level, which is producing compelling clinical results and record financial performance. In the home health and hospice segment, years of rigorous investment and innovation helped us weather the challenging reimbursement environment of the last few years and now positions us to benefit from the more stable payment landscape that appears ahead. On the senior living side, our focus on finding and developing great leaders has enabled us to pursue numerous attractive acquisitions year-to-date, build out local care continuums, and continue to grow our real estate portfolio.
Lynette Walbom
We believe providing updated annual adjusted consolidated EBITDA guidance in addition to updated annual revenue and adjusted earnings per share guidance is helpful to understanding our expectations for our business and operational cash flow. This updated guidance reflects management’s expectations based on year-to-date performance and current operating conditions. Our guidance includes revenue in the range of $196.0 to $198.0 million, adjusted EBITDA in the range of $17.0 to $18.6 million, and adjusted EBITDA prior to NCI of $20.8 to $22.5 million relating to these former UnitedHealth and Amedisys assets.
Informational and educational content only. Not investment advice.